SUNOSI (solriamfetol HCl)
ANTIDEPRESSANT DOPAMINE NOREPINEPHRINE REUPTAKE INHIBITORS · NARCOLEPSY SYNDROME ·+1
Axsome Therapeutics, Inc.
Drug class
Narcolepsy Therapy-Dopamine and Norepinephrine Reuptake Inh.
The phrase "Narcolepsy Therapy-Dopamine and Norepinephrine Reuptake Inh." is a compendial or administrative classification title—most commonly used in pharmacy databases and formularies to describe dopamine and norepinephrine reuptake inhibitors indicated for narcolepsy. Read more about Narcolepsy Therapy-Dopamine and Norepinephrine Reuptake Inh.
1 drugs in this class 1 manufacturers
Drugs in Narcolepsy Therapy-Dopamine and Norepinephrine Reuptake Inh.
Filter & compare in the drug finder →
Opens the drug finder with Narcolepsy Therapy-Dopamine and Norepinephrine Reuptake Inh. preselected. Add indication or manufacturer filters there.
The phrase "Narcolepsy Therapy-Dopamine and Norepinephrine Reuptake Inh." is a compendial or administrative classification title—most commonly used in pharmacy databases and formularies to describe dopamine and norepinephrine reuptake inhibitors indicated for narcolepsy.
Rather than representing a broad therapeutic category, it specifically denotes central nervous system wake-promoting agents such as solriamfetol.
Medications in this group function by selectively binding to and inhibiting both dopamine and norepinephrine transporters, thereby preventing monoamine reuptake and increasing extracellular neurotransmitter concentrations in wake-promoting pathways of the brain.
Clinically, this pharmacologic class is approved to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy and obstructive sleep apnea.
-
pahealthwellness.com
The phrase "Narcolepsy Therapy-Dopamine and Norepinephrine Reuptake Inh." is a compendial or administrative classification title—most commonly used in pharmacy databases and formularies to describe dopamine and norepinephrine reuptake inhibitors indicated for narcolepsy Rather than representing a broad therapeutic category, it specifically denotes central nervous system wake-promoting agents such as solriamfetol Clinically, this pharmacologic class is approved to improve wakefulness and reduce e...
-
modafinil.org
The phrase "Narcolepsy Therapy-Dopamine and Norepinephrine Reuptake Inh." is a compendial or administrative classification title—most commonly used in pharmacy databases and formularies to describe dopamine and norepinephrine reuptake inhibitors indicated for narcolepsy
-
nih.gov
Rather than representing a broad therapeutic category, it specifically denotes central nervous system wake-promoting agents such as solriamfetol Medications in this group function by selectively binding to and inhibiting both dopamine and norepinephrine transporters, thereby preventing monoamine reuptake and increasing extracellular neurotransmitter concentrations in wake-promoting pathways of the brain
-
wakeupnarcolepsy.org
Medications in this group function by selectively binding to and inhibiting both dopamine and norepinephrine transporters, thereby preventing monoamine reuptake and increasing extracellular neurotransmitter concentrations in wake-promoting pathways of the brain
-
pcori.org
Medications in this group function by selectively binding to and inhibiting both dopamine and norepinephrine transporters, thereby preventing monoamine reuptake and increasing extracellular neurotransmitter concentrations in wake-promoting pathways of the brain
-
ajmc.com
Clinically, this pharmacologic class is approved to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy and obstructive sleep apnea
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.